Propanc Biopharma, Inc. filings document a development-stage biopharmaceutical issuer centered on PRP, a proenzyme formulation using trypsinogen and chymotrypsinogen for recurrent and metastatic cancer programs. Registration statements and amendments disclose the company’s business, financial statements, clinical-development plans, risk factors, offering terms, and capital needs.
Material-event reports cover financing and governance actions, including Series C Preferred Stock, related warrants, amendments to charter documents, board changes, and Nasdaq listing-compliance notices. The filing record also details capitalization, preferred-stock rights and conversion mechanics, unregistered equity sales, and public-company reporting obligations tied to Propanc’s oncology development strategy.
Propanc Biopharma, Inc. (PPCB) says its board and majority stockholder approved a reverse split at a ratio between 1 post-split share per 2 pre-split shares and 1 per 10. As of October 8, 2026, 10,331,116 common shares were issued and outstanding. Upon effectiveness, assuming approximately 10,331,116 shares outstanding and issuable as of that date are outstanding immediately beforehand, the company estimates the post-split count would be somewhere between approximately 5,165,558 and 1,033,112 shares, depending on the selected ratio. The split becomes effective when Nasdaq processes and approves it.
Shareholders would retain the same percentage ownership except for fractional shares, which will be rounded up to the nearest whole number. The split will create newly authorized common shares; Propanc says it has no specific issuance plans, though convertible noteholders may elect to convert, and future issuance could dilute earnings per share and book value per share.
Propanc Biopharma, Inc. received board approval and written consent from the holder of a majority of voting power for a reverse split of all outstanding common stock at a ratio from one post-split share per two pre-split shares to one per ten.
As of October 8, 2026, 10,331,116 common shares were issued and outstanding. Assuming that number of shares outstanding and issuable immediately before the split, the projected post-split count is approximately 5,165,558 to 1,033,112 shares, depending on the ratio elected. The split will take effect when Nasdaq processes and approves it. Upon effectiveness, each shareholder will beneficially hold the same percentage, except for fractional-share adjustments rounded up to the nearest whole share. Outstanding options and warrants, if any, will be adjusted so the total prices required to exercise them before and after the split are approximately equal. The split would create newly authorized common shares; the company says it has no specific plans or proposals to issue them, although convertible noteholders may elect to convert their notes into equity. Any issuance would likely dilute earnings per share and book value per share, and could dilute ownership or voting rights or make a change in control more difficult.
Propanc Biopharma, Inc. (PPCB) seeks registration of up to 6,500,000 common shares for resale by selling stockholder Hexstone Capital LLC after the registration statement becomes effective. The shares include shares issuable upon conversion of up to 9,900 Series C preferred shares issuable upon exercise of a warrant. Propanc would receive no proceeds from Hexstone’s resales; it would receive warrant exercise proceeds, including approximately $99 million gross if the warrant is exercised in full for cash. Common shares outstanding were 9,831,116 as of October 1, 2026.
Series C shares convert at the lesser of $125 per share or 85% of the lowest trading price during the Conversion Measuring Period, subject to an effective floor price of $0.05 as of June 30, 2026. The beneficial ownership limit is 4.99%, adjustable to 9.99% upon 61 days’ prior written notice. Propanc says its lead candidate, PRP, remains in preclinical development. For the fiscal year ended June 30, 2026, it reported no revenue, a net loss of $18,862,710 versus $58,923,300 for the fiscal year ended June 30, 2025, and $5,682,635 in net cash used in operations; it also disclosed substantial doubt about its ability to continue as a going concern.
Propanc Biopharma, Inc. (PPCB) reported no revenue and a net loss of $18,862,710 for the year ended June 30, 2026, compared with a net loss of $58,923,300 in the prior year. The company attributed the smaller loss largely to reduced stock-based compensation and stock-based consulting and legal-service expenses. Net cash used in operating activities was $5,682,635, versus $405,168 in fiscal 2025.
At June 30, 2026, cash was $832,006. Financing activities provided $6,457,298, including proceeds from common stock, Series C preferred stock and Series C warrant exercises. Propanc said available cash and current commitments were insufficient to meet obligations over the next 12 months; its auditor reported that the conditions raise substantial doubt about its ability to continue as a going concern.
Propanc is preparing PRP for a planned Phase Ib first-in-human study in 30 to 40 patients with advanced solid tumors. It plans to submit a clinical trial application in the fourth quarter of 2026. The study is planned for the first half of 2027, subject to raising additional sufficient capital.
Propanc Biopharma, Inc. (PPCB) reports that its Board and the holder of a majority of its voting power approved, by written consent dated July 24, 2026, the issuance of restricted shares of common stock to officers, directors and service providers in order to recognize recent achievements and provide incentives.
The awards include 1,000,000 restricted shares to CEO and director James Nathanielsz and multiple grants of 250,000 restricted shares each to various executives, directors, consultants and professional service firms. The approvals are intended to comply with NASDAQ Listing Rules 5635(b) and 5635(c) because PPCB’s common stock trades on the NASDAQ Capital Market and the new issuances implicate NASDAQ’s stockholder-approval standards.
As of July 24, 2026, there were 3,503,116 common shares outstanding and 1 share of Series B Preferred Stock. The Majority Stockholder, James Nathanielsz, held 400,000 common shares and the sole Series B share, representing approximately 50.001% of PPCB’s voting equity, and approved the actions by written consent. No meeting or proxies are being solicited, the actions become effective 20 days after mailing the information statement, and stockholders do not have dissenter’s or appraisal rights for these issuances.
Propanc Biopharma, Inc. obtained stockholder approval by written consent on July 24, 2026 to issue new restricted shares of Common Stock and to implement a reverse stock split, in order to comply with NASDAQ Listing Rules 5635(b) and 5635(c) and maintain its NASDAQ Capital Market listing.
The Board approved restricted share grants to officers, directors and service providers, including 1,000,000 restricted shares to CEO James Nathanielsz and several grants of 250,000 restricted shares to other named recipients. As of July 24, 2026 there were 3,503,116 Common shares and 1 Series B Preferred share outstanding, with the Majority Stockholder holding 400,000 Common shares and the sole Series B Preferred share, representing about 50.001% of voting equity. The actions approved by written consent will become effective 20 calendar days after the first mailing of the Information Statement, and stockholders are not being asked for proxies or granted dissenter’s rights.
Propanc Biopharma, Inc. is registering up to 2,500,000 shares of Common Stock for resale by Hexstone Capital LLC. These shares are issuable upon conversion of up to 9,900 shares of Series C Preferred Stock that may be acquired through a warrant.
Propanc already received $1,000,000 in gross proceeds from issuing 100 Series C Preferred shares and the warrant, and would receive up to $99,000,000 more if the warrant is fully exercised for cash. The company will not receive proceeds from selling stockholder resales. The Series C converts at the lesser of $125.00 or 85% of a volume-based market price, floored at $12.50, subject to a 4.99% (or 9.99% on notice) beneficial ownership cap and a 9,500,000-share reserve.
Shares outstanding were 3,503,116 as of July 6, 2026, or 6,003,116 if all registered shares are issued. Propanc reports no revenue, a nine‑month net loss of $15,221,714, an accumulated deficit of $140,843,234, cash of $443,702, and substantial doubt about its ability to continue as a going concern.
Propanc Biopharma, Inc. reported that effective July 8, 2026, Annie Van Broekhoven retired and stepped down from its Board of Directors, and the company accepted her resignation. The Board simultaneously filled the resulting vacancy.
The Board appointed Carlo Campiciano to serve as a director until his resignation or removal. Campiciano is a qualified accountant and member of the Institute of Public Accountants in Australia, with a Master of Entrepreneurship and Innovation and US GAAP certification. He previously served as CFO and Company Secretary of ASX-listed MedAdvisor Limited, where he helped raise multiple rounds of capital and supported the company’s ASX listing and international expansion. The company and Campiciano entered into a Director Agreement dated July 8, 2026, included as an exhibit.
Propanc Biopharma reported no revenue for the quarter ended March 31, 2026 and remains a development‑stage oncology company focused on its preclinical PRP pro‑enzyme candidate. The company posted a quarterly net loss of $6.36 million and a nine‑month net loss of $14.29 million, driven largely by stock‑based administrative expenses.
Cash increased to $443,702 at March 31, 2026 from $12,088 at June 30, 2025, supported by financing inflows including a common stock offering and issuance of Series C Preferred Stock and related warrants. Total assets were $14.33 million, mostly prepaid equity‑settled service costs, while total liabilities were $3.51 million and stockholders’ equity was $9.83 million.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, negative operating cash flow of $4.08 million over nine months, and a cumulative deficit of $140.84 million. As of May 14, 2026 there were 56,959,280 common shares outstanding, reflecting significant recent equity issuance and conversions.